ENGLEWOOD, Colo., Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...

Available by prescription, this device is designed to offer pain relief via transcutaneous electrical nerve stimulation (TENS) therapy. Founded in 1996, Zynex has been developing, manufacturing ...

Zynex (ZYXI) announced a new partnership to conduct business with Veterans Affairs Medical Centers – VAMCs – across the U.S. It is estimated ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zynex (ZYXI – Research Report) on December 17 and set a price target of $11.00. The company’s shares closed yesterday at $8.17.

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University. Trial completion is a key milestone ...

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...

ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...

On Thursday, H.C. Wainwright maintained a positive stance on shares of Zynex Inc. (NASDAQ:ZYXI), reiterating a Buy rating and a $17.00 price target for the company's stock, representing ...

The projected fair value for Zynex is US$10.75 based on 2 Stage Free Cash Flow to Equity Zynex is estimated to be 22% undervalued based on current share price of US$8.40 Our fair value estimate is 39% ...

Zynex, Inc. operates primarily in the pain management sector, with a growing interest in patient monitoring technologies. The company's business model revolves around developing and marketing medical ...